FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndrome

The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.

Related Keywords

United States , , Servier Pharmaceuticals , Drug Administration , Abbott Realtime , Myelodysplastic Syndrome , Ads , Refractory , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Hematopoietic Stem Cell Transplantation , Stem Cell Transplantation , Stem Cell Therapy , Herapy Stem Cell , Remission , Biologic Therapy , Acute Leukemia , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Hepatocellular Carcinoma , Liver Cancer , Dcc , Epatocell ,